Dendritic Cells in Colorectal Cancer and a Potential for their Use in Therapeutic Approaches

Title:Dendritic Cells in Colorectal Cancer and a Potential for their Use in Therapeutic Approaches

Volume: 22 Issue: 16

Author(s): Dimitry A. Chistiakov, Alexander N. Orekhov and Yuri V. Bobryshev

Affiliation:

Keywords: Colorectal cancer, dendritic cells, immune reactions, therapeutic approaches.

Abstract: Multiple pathogenic mechanisms contribute to the development of colorectal cancer. This tumor is characterized by high chemoresistance and low immunogenicity due to the effective mechanisms of immunosuppression. Dendritic cells (DCs) play a key role in recognition of tumor antigens and induction of T-cell-primed anticancer response. However, in cancer microenvironment, the function of tumor-infiltrating DCs becomes impaired and switched from the immunostimulation to the immunosuppression. Colorectal cancer cells express anti-inflammatory cytokines such as IL-10 and TGF-β that could affect DC phenotype and support tumor escape from the immune surveillance. As a result, tumor-associated DCs display numerous defects in antigen-presenting capacity and have an altered pattern of expression of immune costimulatory molecules towards the immunoregulatory phenotype. Indeed, understanding of mechanisms, such as how tumor could impair activity of DCs, would help in the development of new DC-based vaccines against colorectal cancer.

Cite this article as:

A. Chistiakov Dimitry, N. Orekhov Alexander and V. Bobryshev Yuri, Dendritic Cells in Colorectal Cancer and a Potential for their Use in Therapeutic Approaches, Current Pharmaceutical Design 2016; 22 (16) . https://dx.doi.org/10.2174/1381612822666160203141740